| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AVTX | Common Stock | Purchase | $216K | +95.5K | +0.24% | $2.26 | 39.4M | Sep 15, 2021 | See Footnote | F1, F2 |
| transaction | AVTX | Common Stock | Purchase | $342K | +150K | +0.38% | $2.28 | 39.5M | Sep 16, 2021 | See Footnote | F1, F3 |
| transaction | AVTX | Common Stock | Purchase | $12M | +5.45M | +13.79% | $2.20 | 45M | Sep 17, 2021 | See Footnote | F1 |
| holding | AVTX | Common Stock | 412K | Sep 15, 2021 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | The reported securities of Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1461 to $2.3594, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1874 to $2.3089, inclusive. |
| F4 | These shares are directly owned by Mr. Boyd in his personal capacity. |
Each of the Master Fund and Armistice Capital may be deemed a director by deputization of the Issuer by virtue of the fact that Steven Boyd, a representative of the Master Fund and Armistice Capital, currently serves on the Issuer's board of directors.